DexCom (DXCM) to Release Earnings on Thursday

DexCom (NASDAQ:DXCM) will likely be releasing its Q4 2025 results after the market closes on Thursday, February 12th. Analysts expect the company to announce earnings of $0.65 per share and revenue of $1.2520 billion for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 12, 2026 at 4:30 PM ET.

DexCom Stock Down 1.1%

DexCom stock opened at $70.83 on Thursday. The firm has a market capitalization of $27.63 billion, a price-to-earnings ratio of 39.35, a P/E/G ratio of 1.28 and a beta of 1.49. DexCom has a 1-year low of $54.11 and a 1-year high of $93.25. The company has a current ratio of 1.56, a quick ratio of 1.38 and a debt-to-equity ratio of 0.45. The firm has a 50 day simple moving average of $68.39 and a 200 day simple moving average of $70.50.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on DXCM shares. Royal Bank Of Canada cut their price objective on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating for the company in a research report on Friday, October 31st. Barclays cut shares of DexCom from an “equal weight” rating to an “underweight” rating and decreased their price target for the stock from $80.00 to $71.00 in a report on Monday, January 12th. Piper Sandler set a $75.00 target price on DexCom and gave the stock a “buy” rating in a research report on Friday, October 31st. Truist Financial restated a “buy” rating and issued a $82.00 target price (down from $94.00) on shares of DexCom in a research note on Monday, November 3rd. Finally, Leerink Partners reiterated an “outperform” rating and set a $92.00 price target on shares of DexCom in a research report on Tuesday, December 16th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $85.00.

Insider Activity

In related news, COO Jacob Steven Leach bought 18,200 shares of the company’s stock in a transaction that occurred on Monday, November 10th. The stock was bought at an average cost of $55.04 per share, for a total transaction of $1,001,728.00. Following the acquisition, the chief operating officer directly owned 331,697 shares of the company’s stock, valued at $18,256,602.88. The trade was a 5.81% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Richard Alexander Collins sold 2,906 shares of the business’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $59.05, for a total value of $171,599.30. Following the completion of the sale, the director owned 35,088 shares of the company’s stock, valued at $2,071,946.40. The trade was a 7.65% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 7,866 shares of company stock valued at $448,177. Corporate insiders own 0.32% of the company’s stock.

Institutional Trading of DexCom

Institutional investors have recently modified their holdings of the company. Quarry LP bought a new position in DexCom during the 3rd quarter valued at approximately $72,000. Palisade Asset Management LLC purchased a new stake in shares of DexCom in the 3rd quarter worth about $81,000. MUFG Securities EMEA plc bought a new stake in shares of DexCom during the 2nd quarter valued at about $100,000. Banque Transatlantique SA increased its position in shares of DexCom by 71.2% during the second quarter. Banque Transatlantique SA now owns 1,500 shares of the medical device company’s stock valued at $131,000 after buying an additional 624 shares during the period. Finally, Brown Brothers Harriman & Co. raised its stake in DexCom by 29.9% in the third quarter. Brown Brothers Harriman & Co. now owns 2,344 shares of the medical device company’s stock worth $158,000 after buying an additional 540 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.